Geldards Advise XenoGesis On Its Sale To The Sygnature Group

Geldards’ Midlands-based Corporate team have successfully advised the shareholders of XenoGesis on its sale to a world-leading integrated discovery and pre-clinical solutions provider, Sygnature Group.

XenoGesis has become the UK’s largest independent DMPK CRO with a growing global client base, having attained a strong track record of success through its novel consultative approach and high quality science and forward-thinking methodologies.

Having recently broadened its integrated drug discovery offering through strategic acquisitions, Sygnature’s acquisition of XenoGesis serves to meet an increasing demand for its services and boost the company’s reach into the pre-clinical space.

Located at BioCity in Nottingham, both companies have an ethos of having co-located, multi-disciplinary teams of expert research scientists working efficiently together to facilitate seamless drug discovery and creating innovative solutions for its partners.

The Geldards team was led by Partner Jenny Chatten and supported by Associate Sarah Bailey. Commenting on the transaction, Jenny, said:

“We are delighted to have worked with Richard Weaver and the other shareholders of XenoGesis on this transaction. We have been working with XenoGesis for some time, and it has been wonderful to see them go from strength to strength. There is a strong synergy with the team at Sygnature, and this is a great opportunity for these two successful local drug discovery businesses to expand and grow together.”